Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:41:54 2024-12-13 am EST			5-day change	1st Jan Change
75.90 ^USD	-1.02%		+3.78%	-0.62%

Dec. 12	Bio-Techne Signs Distribution Deal With MedSanTek to Expand Product Reach in Turkey	MT
Dec. 12	Medsantek Co. Partners with Bio-Techne Corporation to Bring World-Class Products and Diagnostics in Turkey and Azeri Markets	CI

BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES

November 11, 2024 at 10:37 am EST

MINNEAPOLIS - Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference

November 12, 2024

9:30 AM PST

Stifel 2024 Healthcare Conference

November 19, 2024

8:00 AM EST

Stephens NASH 2024 Conference

November 20, 2024

11:00 AM CST

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide.

Contact:

David Clair

Email: david.clair@bio-techne.com

Tel: 612-656-4416

Latest news about Bio-Techne Corporation

Bio-Techne Signs Distribution Deal With MedSanTek to Expand Product Reach in Turkey	Dec. 12	MT
Medsantek Co. Partners with Bio-Techne Corporation to Bring World-Class Products and Diagnostics in Turkey and Azeri Markets	Dec. 12	CI
Bio-Techne Corporation Presents at Citi's 2024 Global Healthcare Conference, Dec-04-2024 03:15 PM	Dec. 04
Bio-Techne's Select Fetal Bovine Serum Product Rights, Inventory Acquired by Gemini Bioproducts	Nov. 25	MT
Gemini Bio-Products, Inc. acquired Assets of Bio-Techne Corporation.	Nov. 24	CI
Bio-Techne Corporation Presents at Stephens 26th Annual Investment Conference \| NASH2024, Nov-20-2024 11:00 AM	Nov. 20
Bio-Techne Signs Distribution Deal With Leader Life Sciences	Nov. 20	MT
Bio-Techne Corporation Announces New Distribution Agreement with Leader Life Sciences	Nov. 20	CI
Bio-Techne Corporation Presents at Stifel 2024 Healthcare Conference, Nov-19-2024 08:00 AM	Nov. 19
Bio-Techne Corporation and ALZpath, Inc Announce Strategic Partnership to Advance Neurodegenerative Disease Research	Nov. 18	CI
Bio-Techne Corporation to Highlight Novel Solutions for Cancer and Carrier Screening At Amp 2024 Annual Meeting & Expo	Nov. 14	CI
Bio-Techne Corporation Presents at UBS Global Healthcare Conference 2024, Nov-12-2024 09:30 AM	Nov. 12
Bio-Techne Corporation to Present at the Society for Immunotherapy of Cancer 39Th Annual Meeting	Nov. 06	CI
Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on February 1, 2022.	Nov. 05	CI
Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data	Nov. 05	CI
Scotiabank Adjusts Bio-Techne's Price Target to $88 From $83	Oct. 31	MT
Baird Adjusts Bio-Techne's Price Target to $84 From $82	Oct. 31	MT
Stifel Adjusts Bio-Techne's Price Target to $75 From $65	Oct. 31	MT
RBC Adjusts Bio-Techne's Price Target to $79 From $77	Oct. 31	MT
Bio-Techne Corporation, Q1 2025 Earnings Call, Oct 30, 2024	Oct. 30
Earnings Flash (TECH) BIO-TECHNE CORPORATION Posts Q1 Revenue $289.5M	Oct. 30	MT
Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q1 EPS $0.42	Oct. 30	MT
Bio-Techne Corporation Reports Earnings Results for the First Quarter Ended September 30, 2024	Oct. 30	CI
ScaleReady and Bio-Techne Corporation Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies	Sep. 16	CI
RBC Raises Price Target on Bio-Techne to $77 From $70, Keeps Sector Perform Rating	Sep. 13	MT

Chart Bio-Techne Corporation

Duration

Period

TECH: Dynamic Chart

Company Profile

Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools 71.5%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (28.1%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. ; - other (0.4%). Net sales are distributed geographically as follows: the United States (56.7%), the United Kingdom (4.3%), Europe-Middle East-Africa (20.8%), China (8.6%), Asia-Pacific (6.5%) and others (3.1%).

Employees

3,100

Sector

Biotechnology & Medical Research

Calendar

2025-02-03 - Q2 2025 Earnings Release (Projected)

More about the company